Intravitreal implantation of Ozurdex® chronic delivery system for management of macular edema related to retinitis pigmentosa: Case report;Implante intravítreo de liberação crônica de dexametasona (Ozurdex®) para o tratamento de edema macular por retinose pigmentar: Relato de caso

Arquivos Brasileiros de Oftalmologia

Volumn 76, Issue 6, 2013, Pages 377-379

  Buchaim, Guilherme ^a,b   Rezende, Marcussi Palata ^a,b   Maia, Maurício ^a,b  

^a Brazilian Institute of Fighting Against Blindness   (Brazil)

^b UNIVERSIDADE DO OESTE PAULISTA UNOESTE   (Brazil)

Author keywords

Adult; Case report; Dexamethasone administration dosage; Drug implants; Female; Humans; Injections; Macular edema drug therapy; Retinitis pigmentosa complications Macular edema etiology; Visual acuity

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID;

ARTICLE; CASE REPORT; DRUG IMPLANT; FEMALE; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; METHODOLOGY; RETINA MACULA EDEMA; RETINITIS PIGMENTOSA; TIME; TREATMENT OUTCOME; VISUAL ACUITY; YOUNG ADULT;

DEXAMETHASONE; DRUG IMPLANTS; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; RETINITIS PIGMENTOSA; TIME FACTORS; TREATMENT OUTCOME; VISUAL ACUITY; YOUNG ADULT;

EID: 84894032363     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492013000600013     Document Type: Article

References (8)

1. Saraiva VS, Sallum JM, Farah ME. Treatment of cystoid macular edema related to retinitis pigmentosa with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging. 2003;34(5):398-400.
2. Sahel J, Vonnel S, Mrejen S, Paques, M. Retinitis pigmentosa and others dystrophies. Dev Ophthalmol. 2010;47:160-7.
3. Loukianou E, Kisma N, Pal B. Evolution of an astrocytic hamartoma of the optic nerve head in a patient with retinitis pigmentosa-photographic documentation over 2 years of follow-up. Case Rep Ophthalmol; 2011;2(1):45-9.
4. Chieh JJ, Roth DB, Liu M, Belmont J, Nelson M, Regillo C, et al. Intravitreal triamcinolone acetonide for diabetic macular edema. Retina. 2005;25(7):828-34.
5. Audren F, Tod M, Massin P, Benosman R, Haouchine B, Erginay A, et al. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2004;45(10):3435-41.
6. Lowder C, Belfort R Jr., Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM; Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5): 545-53. Comment in: Arch Ophthalmol. 2011; 129(12):1638-9; author reply 1639-40.
7. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM; Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118(12):2453-60. Comment in: Ophthalmology. 2012;119(12):2654-5.e1; author reply 2655.
8. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127(9):1101-14. Erratum in: Arch Ophthalmol. 2009;127(12):1648. Comment in: JAMA. 2009;302(15):1693-5; Arch Ophthalmol. 2009;127(9):1203-4.